⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11518996 | 0.84 | — | — | |
| SCHEMBL30201312 | 0.73 | ADRB2 (0.30) | — | |
| SCHEMBL14952873 | 0.71 | — | — | |
| SCHEMBL8844169 | 0.71 | HRH3 (0.32) | — | |
| SCHEMBL11498129 | 0.68 | PLA2G2A (0.33) | — | |
| SCHEMBL6617322 | 0.68 | NEK2 (0.32) | — | |
| SCHEMBL16741919 | 0.63 | CHRM3 (0.30) | — | |
| SCHEMBL3715845 | 0.62 | SMARCA2 (0.30) | — | |
| Iodide SCHEMBL7846998 | 0.59 | — | — | |
| SCHEMBL30752302 | 0.59 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2594258-B1 | Oral gel comprising praziquantel | VETERINAERMEDIZINISCHE UNIV WIEN (AT) | 2020-03-18 | — | — | EP | disclosed |
| EP-3612532-A1 | VMAT2 INHIBITOR COMPOUNDS AND COMPOSITIONS THEREOF | Neurocrine Biosciences, Inc. (US) | 2020-02-26 | — | — | EP | disclosed |
| WO-2018195121-A1 | VMAT2 INHIBITOR COMPOUNDS AND COMPOSITIONS THEREOF | NEUROCRINE BIOSCIENCES, INC. (US) | 2018-10-25 | — | — | WO | disclosed |
| WO-2017158151-A1 | PYRIMIDONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | SAVIRA PHARMACEUTICALS GMBH (AT) | 2017-09-21 | — | — | WO | disclosed |
| EP-2594258-A1 | Oral gel comprising praziquantel | Veterinärmedizinische Universität Wien (AT) | 2013-05-22 | — | — | EP | disclosed |
| EP-0971721-A1 | USE OF BACTERIAL CELL WALL EXTRACT FOR PREVENTING, TREATING, OR ELIMINATING A PROTOZOAL OR PARASITIC DISEASE | Bioniche Inc. (CA) | 2000-01-19 | — | — | EP | disclosed |
| WO-1998043656-A1 | USE OF BACTERIAL CELL WALL EXTRACT FOR PREVENTING, TREATING, OR ELIMINATING A PROTOZOAL OR PARASITIC DISEASE | BIONICHE INC. (CA) | 1998-10-08 | — | — | WO | disclosed |